Search results: (10000)
News The Immune System in the Pathophysiology of ITP
From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.
News Experience from Clinical Practice with Intestinal Gel LECIG in Treating Parkinson's Disease
A Swedish observational study evaluated the applicability of the LECIG intestinal gel, which contains levodopa (20 mg/ml), carbidopa (5 mg/ml), and entacapone (20 mg/ml), in clinical practice for patients with Parkinson's disease.
News Results of Long-Term Follow-Up of Patients with Prostate Adenocarcinoma After Radiotherapy with Short-Term Androgen Deprivation
Adding short-term androgen deprivation to radiotherapy improved overall survival, disease-specific mortality, and the incidence of distant metastases in men diagnosed with prostate adenocarcinoma. Subsequent analysis investigated whether the beneficial effect of androgen deprivation is long-lasting.
News New Technology Teaches Healthcare Professionals to Deliver Messages Patients Don't Want to Hear
Communication with patients and their relatives is often very challenging for doctors and nurses, especially when the patient or their family member is experiencing strong emotions. A new technology from the startup ComGuide is here to help healthcare professionals practice how to communicate most effectively. Jan Hrdlička, the co-author, explained how exactly this technology works, who it is suitable for, and how it was developed and continues to evolve.
News Efficacy of Bisoprolol in Patients After Acute MI with LV Systolic Dysfunction
What impact does one year of bisoprolol use have in real-world practice on heart rate, left ventricular ejection fraction (LVEF), glycated hemoglobin (HbA1c) levels, or lipid profile in patients after acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD)? This was investigated by the authors of a study whose results were published last year.
News Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies – Case Reports
German authors last year described the first 2 cases of patients with psoriasis in whom treatment with, among other things, anti-IL-17A antibodies failed, but who responded to the blockade of interleukins IL-17A/IL-17F with bimekizumab after its approval by the European Medicines Agency (EMA).
News Neutropenia with Thrombocytopenia after Alemtuzumab? − Case Report
Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the patient in the following case report by Italian colleagues was affected. What was the outcome?
News New Alternative in the Treatment of Diffuse Large B-cell Lymphoma
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable candidates for autologous stem cell transplantation, a wide range of treatment regimens is available. Recently, the addition of polatuzumab vedotin to rituximab and bendamustine therapy has shown promising efficacy in both registration studies and real-world clinical practice.
News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases
Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.
News Asthma and Prognosis of Patients with COVID-19
The impact of asthma, its severity, and treatment on the prognosis of patients infected with the SARS-CoV-2 coronavirus was examined in an observational study published this spring.
News Can the Fixed Combination of Tramadol/Acetaminophen Significantly Reduce Back Pain Uncontrolled by NSAIDs?
One way to prevent drug-related complications in the treatment of lower back pain (LBP) while improving patients' functioning in daily activities is the prescription of the weak opioid agonist tramadol in combination with acetaminophen. A smaller Japanese observational study focused on the effectiveness of this treatment in reducing the disability of patients with chronic LBP, improving their daily activities, and the occurrence of adverse events.
News Asthma is not a risk factor for a severe course of COVID-19
According to the statement of the Czech Initiative for Asthma from April 2020, the disease COVID-19 caused by the new type of coronavirus does not pose significantly greater danger for people with asthma than for the general population. It is, however, necessary to adhere to the prescribed treatment and keep asthma under control. The Journal of Allergy and Clinical Immunology provides an explanation for this surprising phenomenon. It is the reduced expression of ACE2 receptors in people with asthma and allergies, as shown by a new study involving three cohorts of pediatric and adult patients. The SARS-CoV-2 virus uses ACE2 receptors to enter the host cell.
News How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?
Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
News Intestinal Gel LECIG in the Treatment of Advanced Parkinson's Disease in Real Practice
A recently published study presents the first experiences with an intestinal gel containing a triple combination of antiparkinsonian drugs and dosed via an infusion pump through percutaneous endoscopic gastrostomy extended into the jejunum in the treatment of advanced Parkinson's disease.
News Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the treatment of ulcerative colitis (UC) in adult patients. We summarize the results of the phase III placebo-controlled True North study published in the New England Journal of Medicine, which demonstrated efficacy and safety in both induction and maintenance therapy for UC.
News Management of Musculoskeletal Issues in Hemophiliacs at a Glance
Musculoskeletal issues are among the most common complications of hemophilia. Prevention and early treatment are crucial, and this message is also addressed to specialists by the World Federation of Hemophilia (WFH) guidelines from 2020.
News Efficacy of Hyaluronic Acid Eye Drops in the Treatment of Dry Eye Syndrome – Results of a Meta-Analysis
Dry eye syndrome affects 5–30% of individuals over the age of 50. The beneficial effect of hyaluronic acid on the symptoms of this condition has been well described in both preclinical and clinical studies, and it has been shown that its topical application increases the secretion of water and mucin on the surface of the eye. The meta-analysis presented below focused on the efficacy of eye drops containing hyaluronic acid in the treatment of dry eye syndrome.
News ESC 2022: How to use gliflozins in heart failure? American guidelines now also consider the EMPEROR-Preserved study
One of the important current cardiology topics is the possibility of using gliflozins in patients with chronic heart failure (HF) regardless of the left ventricular ejection fraction (LVEF). The possibilities of introducing these medicines into clinical practice, considering the issue in international guidelines, and the results of empagliflozin in recent studies were covered in a practically oriented symposium as part of the professional program of this year's European Society of Cardiology Congress (ESC 2022).
News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.
News Thyroid Disorder Screening in Pregnancy to Be Tested by Pilot Program Starting September
The expectations surrounding the trial launch of the screening program were discussed by Professor Michal Kršek, Chairman of the Czech Endocrinological Society ČLS JEP, on the occasion of the 12th annual “Thyroid Week”.
News New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy
Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.